Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has scheduled a webinar for Tuesday, September 2, 2025, at 8:00 a.m. ET to announce their lead in vivo development candidate. The presentation will be accessible through a webcast link and the company's investor relations website.
The webinar will focus on revealing details about their latest advancement in gene editing technology aimed at developing transformative medicines for serious diseases. A replay will be available in the Investors section of the Editas Medicine website following the presentation.
Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced its participation in three major healthcare investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York featuring a fireside chat at 11:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 in New York.
Live webcasts of available presentations can be accessed through the Investors section of Editas Medicine's website, with replays available for approximately 30 days after each event.
[]Editas Medicine (Nasdaq: EDIT) reported Q2 2025 financial results and business updates. The company plans to select its first in vivo development candidate in September, targeting an IND filing by mid-2026 and human proof-of-concept by year-end 2026. Key highlights include the acceptance of first IND/CTA for CD19 HD Allo CAR T program with Bristol Myers Squibb and presentation of promising preclinical data at multiple scientific conferences.
Financial results show a net loss of $53.2 million ($0.63 per share), improved from $67.6 million loss in Q2 2024. The company maintains a strong cash position of $178.5 million, providing runway into Q2 2027. Research and development expenses decreased to $16.2 million from $54.2 million year-over-year, while restructuring charges were $26.1 million related to the discontinuation of the reni-cel program.
Editas Medicine (NASDAQ: EDIT) announced the acceptance of new preclinical data for presentation at the European Hematology Association (EHA) 2025 Congress in Milan. The study, conducted in non-human primates, demonstrates promising results for their in vivo hematopoietic stem cell (HSC) gene editing program targeting sickle cell disease and beta thalassemia.
Key findings include high-efficiency HSC delivery, therapeutically relevant editing levels in the HBG1/2 promoter region exceeding 25% threshold with a single dose, and favorable biodistribution using Editas' targeted lipid nanoparticle (tLNP) technology. The data shows significant liver de-targeting compared to standard LNPs, supporting further development of their proprietary HSC-tLNP platform.
In non-human primates, a single intravenous dose achieved up to 47% HBG1/2 editing levels in HSCs. In humanized mice, the treatment reached 48% editing in long-term HSCs. Both results exceeded the 25% threshold required for therapeutic benefit.
The company's tLNP formulation showed improved liver de-targeting compared to standard LNPs, and utilizes proprietary AsCas12a technology for high-efficiency editing while minimizing off-target effects. The approach mimics naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH).
- ~70% maximal liver editing and >80% disease biomarker reduction in mouse models
- >50% target gene editing and >15-fold protein upregulation in cynomolgus monkey hepatocytes
Editas Medicine (NASDAQ: EDIT) announced that the U.S. Court of Appeals for the Federal Circuit has partially affirmed and partially vacated the Patent Trial and Appeal Board's (PTAB) previous decision regarding CRISPR/Cas9 patent interference. The case involves patents between the University of California, University of Vienna, and Emmanuelle Charpentier versus the Broad Institute.
The company emphasized that its in-licensed CRISPR/Cas12a patents are unaffected by this decision. Editas holds exclusive licenses to Harvard and Broad Institute's Cas9 patent estates for human medicine development. The company maintains a robust IP portfolio including fundamental patents for both CRISPR/Cas12a and CRISPR/Cas9 gene editing in human cells across multiple jurisdictions including the US, Europe, China, and Japan.
Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced it will release its Q1 2025 financial results on May 12, 2025 through a press release and SEC filings. The company has discontinued its practice of hosting quarterly financial results conference calls.
Additionally, Editas management will participate in the Bank of America Global Healthcare Conference in Las Vegas on May 13, 2025 at 5:15 p.m. PT in a fireside chat format. The presentation will be accessible via webcast on the company's website, with a replay available for approximately 30 days.